Conduct Early-Phase Studies to Improve Manufacturability and Mitigate Risk

Home | Conduct Early-Phase Studies to Improve Manufacturability and Mitigate Risk

Creating effective, scalable manufacturing strategies for adeno-associated virus (AAV) therapies means sponsors and contract development and manufacturing organizations (CDMOs) must identify creative and collaborative solutions in the early phases of development. In a recent webinar hosted by FUJIFILM Biotechnologies, Ian Goodwin, Director of CMC Program Design, provided his expert insight into the benefits of implementing early-phase studies like candidate screening and feasibility assessments for AAV manufacturing. In the post-webinar Q&A session, Goodwin tackled listener questions on manufacturability vs. clinical efficacy, regulatory support, and more.

Primary Interest(Required)
Segments(Required)
Sub-Segments(Required)
Privacy Policy(Required)
By submitting this form I agree that FUJIFILM Biotechnologies may process my data in the manner described in FUJIFILM’s Privacy Policy